Terms: = Thyroid cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Prognosis
9 results:
1. Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the pai-1/ERK pathway.
Li Y; Fan L; Yan A; Ren X; Zhao Y; Hua B
J Transl Med; 2024 Jan; 22(1):112. PubMed ID: 38282047
[TBL] [Abstract] [Full Text] [Related]
2. Using The cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on cancer staging for papillary thyroid carcinoma.
Poma AM; Macerola E; Torregrossa L; Elisei R; Santini F; Basolo F
Endocrine; 2021 Apr; 72(1):140-146. PubMed ID: 32915437
[TBL] [Abstract] [Full Text] [Related]
3. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma.
Wang J; Chen X; Tian Y; Zhu G; Qin Y; Chen X; Pi L; Wei M; Liu G; Li Z; Chen C; Lv Y; Cai G
Aging (Albany NY); 2020 Jan; 12(1):767-783. PubMed ID: 31927533
[TBL] [Abstract] [Full Text] [Related]
4. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract] [Full Text] [Related]
5. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract] [Full Text] [Related]
6. Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells.
Chen CY; Chi LM; Chi HC; Tsai MM; Tsai CY; Tseng YH; Lin YH; Chen WJ; Huang YH; Lin KH
Mol Cell Proteomics; 2012 Apr; 11(4):M111.011270. PubMed ID: 22171322
[TBL] [Abstract] [Full Text] [Related]
7. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract] [Full Text] [Related]
8. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
[TBL] [Abstract] [Full Text] [Related]
9. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Ito Y; Takeda T; Kobayashi T; Wakasugi E; Tamaki Y; Umeshita K; Monden T; Shimano T; Monden M
Anticancer Res; 1996; 16(1):81-9. PubMed ID: 8615674
[TBL] [Abstract] [Full Text] [Related]
